Top Markets
#1 WYDE: End Hunger WYDE: End Hunger +2.71%
#2 MetaDAO MetaDAO +2.37%
#3 StonkBroker StonkBroker +2.30%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +2.27%
#5 PulseX PulseX +1.94%
#6 The Grays Currency The Grays Currency +1.93%
#7 Dual Dual +1.86%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +1.67%
#9 Fractal Bitcoin Fractal Bitcoin +1.59%
#10 Wrapped Pulse Wrapped Pulse +1.56%
Coin of the day
WYDE: End Hunger WYDE: End Hunger
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
Classifica tra le azioni #19939
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Prezzo delle azioni
$3.88
Ultima sincronizzazione: 2026-08-25
Capitalizzazione di mercato
$146.08M
Variazione (1 giorno)
-0.51%
Variazione (1 anno)
63.71%
Paese
CN
Scambia Adagene Inc. (ADAG)

Categoria

Healthcare
Storico dividendi per Adagene Inc. (ADAG)
Adagene Inc. (simbolo azionario: ADAG) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Adagene Inc. (ADAG) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH